全球生物模拟市场规模、份额、成长分析、按应用（药物开发、药物发现）、最终用户（製药和生物技术公司、学术机构和研究实验室）- 2024-2031 年产业预测

Global Biosimulation Market Size, Share, Growth Analysis, By Application(drug development, drug discovery), By End user(pharmaceutical and biotechnology companies, academic institutes and research laboratories) - Industry Forecast 2024-2031

出版日期: 2024年04月27日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球生物模拟市场规模为28.1亿美元，预计将从2023年的32.8亿美元成长到2031年的114.6亿美元，在预测期间（2024-2031年）复合年增长率为16.90%。

生物模拟利用电脑程式模拟生物过程，透过预测未来的实验结果，在药物发现和开发中找到了多种应用。考虑到后期药物开发涉及的巨大成本和资源，它在预测药物分子的功效和潜在失败方面的作用至关重要。特别值得注意的是，在 COVID-19 大流行期间，其需求激增，其在疫苗开发中的关键作用证明了这一点。例如，领先的生物模拟技术公司 Certara 迅速调整其服务以协助疫苗开发商，强调了对生物模拟工具的高度依赖来应对药物开发挑战，从而推动市场成长。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 欧洲其他地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 拉丁美洲其他地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- MEA 的其余部分

竞争格局

前 5 名玩家比较
2023 年关键参与者的市场定位
主要市场参与者所采取的策略
最佳制胜策略
近期市集活动
主要公司市占率 (%), 2023

主要公司简介

Certara
Dassault Systemes SE
Simulations Plus Inc.
Schrodinger Inc.
Physiomics Plc
Advanced Chemistry Development Inc.
In silico biosciences Inc.
Genedata AG
Evidera Inc.
Leadscope Inc.
Insilico Biotechnology AG
Rhenovia Pharma SAS
Entelos Inc.
Biocomputing Platforms Ltd.
Rosa & Co. LLC
Genedata AG
OpenEye Scientific Software Inc.
Nexelis
Compugen Ltd.
Chemical Computing Group ULC

简介目录

Product Code: SQMIG35I2104

Global Biosimulation Market size was valued at USD 2.81 billion in 2022 and is poised to grow from USD 3.28 billion in 2023 to USD 11.46 billion by 2031, growing at a CAGR of 16.90% during the forecast period (2024-2031).

Biosimulation, utilizing computer programs to simulate biological processes, finds diverse applications in drug discovery and development by enabling prediction of future outcomes of experiments. Its role in foreseeing the efficacy and potential failures of drug molecules is crucial, given the immense costs and resources involved in late-stage drug development. Particularly notable is its surge in demand during the COVID-19 pandemic, as evidenced by its pivotal role in vaccine development. For instance, Certara, a leading biosimulation technology company, swiftly adapted its services to assist vaccine developers, underscoring the heightened reliance on biosimulation tools to navigate drug development challenges, thereby fueling market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biosimulation Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biosimulation Market Segmental Analysis

The global biosimulation market is divided into three sections: offering type, application, and end user. The market is classified into two types of offerings: software and services. The software segment is divided into the following categories: PK/PD modelling and simulation, PBPK modelling and simulation, trial simulators, molecular modelling, and others. The Biosimulation Market is classified into three applications: drug discovery, drug development, and others. End users in the Biosimulation Market include contract research organisations, pharmaceutical and biotechnology companies, research institutes, regulatory institutes, and others. By region, the Biosimulation Market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Biosimulation Market

The global biosimilars market is witnessing growth propelled by multiple factors. These include the mounting imperative to reduce healthcare expenditures, heightened interest in cost-effective biosimilars, escalating incidence rates of diverse diseases, expanding array of off-patent drugs, promising outcomes from ongoing clinical trials, and surging demand for biosimilars across therapeutic domains like rheumatoid arthritis and blood disorders.

Restraints in the Global Biosimulation Market

The utilization of biosimulation technologies in drug discovery and development lacks standardization, employing various models and techniques to register and process diverse biological events. Due to the heightened complexity, storing, modifying, and sharing data and models pose challenges for researchers. Standardization is essential to ensure the production of dependable and efficient outcomes. However, the absence of standards from regulatory authorities stands as a major impediment to the expansion of the biosimulation industry.

Market Trends of the Global Biosimulation Market

A primary factor propelling market expansion is the escalating occurrence of drug relapse incidents linked to drug resistance in ailments like cancer, tuberculosis, and bacterial infections. Furthermore, the market is influenced by heightened governmental funding aimed at fostering the uptake of these remedies. Moreover, the biosimulation sector gains from augmented healthcare expenditure, enhancements in healthcare infrastructure, and a growing demand for comprehensive care provision.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Biosimulation Market by Application

Market Overview
drug development
drug discovery
and others

Global Biosimulation Market by End user

Market Overview
pharmaceutical and biotechnology companies
academic institutes and research laboratories
contract research organisations
and others

Global Biosimulation Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Certara
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dassault Systemes SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Simulations Plus Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Schrodinger Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Physiomics Plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Advanced Chemistry Development Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
In silico biosciences Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genedata AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Evidera Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Leadscope Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Insilico Biotechnology AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Rhenovia Pharma SAS
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Entelos Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocomputing Platforms Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Rosa & Co. LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genedata AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OpenEye Scientific Software Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nexelis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Compugen Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chemical Computing Group ULC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments